Dr. Patrick Baeuerle argues the biggest challenge for cell engagers and CAR-T therapies is not killing power but the tumor's ability to down-regulate or lose the target antigen. This heterogeneity is a fundamental escape mechanism that future multi-targeting strategies must address to prevent relapse.
Both experts advocate shifting immune cell engager use from late-stage, high-burden cancer to a minimal residual disease (MRD) setting. Treating a low tumor load maximizes the effector-to-target ratio, enhances efficacy, and significantly reduces side effects, potentially moving these therapies to first-line combinations.
Incorporating IL-15 into NK-cell engagers goes beyond simple co-stimulation; it actively expands the NK cell population in the patient's body. This overcomes the naturally low number of NK cells relative to T cells, boosting the effector-to-target ratio and enhancing the therapy's overall potency.
NK-cell engagers produce significantly fewer secondary inflammatory cytokines, like IL-6, compared to T-cell engagers. This fundamental biological difference could make them safer and more suitable for administration in community settings, lowering a key barrier to adoption for potent immunotherapies.
Many promising solid tumor antigens (e.g., PSMA, HER2) are also on normal tissues, making them too toxic for T-cell engagers. By using masks that are cleaved only in the tumor microenvironment, these "dirty" targets become viable, dramatically expanding the therapeutic landscape for solid cancers.
Unlike CAR-T therapies that rely on a limited number of engineered cells, T-cell engagers activate the body's entire T-cell repertoire. This vast pool of effector cells makes exhaustion a negligible issue, as only a small fraction is engaged at any time, ensuring a sustained attack on cancer cells.
Dr. Patrick Baeuerle suggests that instead of engineering complex co-stimulatory signals into T-cell engagers, a more effective strategy is to combine them with standard-of-care treatments like chemotherapy or ADCs. This approach dramatically augments efficacy and has already prompted multiple Phase 3 trials.
While targeting intracellular peptide-MHC complexes opens the entire proteome as potential cancer targets, the approach is limited by HLA restriction. This means a drug might only be applicable to 30-40% of patients, a major commercial and clinical drawback that complicates development despite the potential for exquisite specificity.